Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy

Starting soon

Conditions studied: Chemotherapy Induced Peripheral Neuropathy (CIPN)

In brief

The purpose of this observational, data collection, research is to evaluate if ziconotide, a commercially approved medication given by a FDA cleared intrathecal pump, for chronic pain is effective in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) a common and often long-lasting side effect of cancer treatment.

Key facts

Study ID
NCT07499882
Run by
Christian Hospital Northeast Northwest
People needed
24
Starts
2026-05-02
Expected to finish
2028-05-01
Last updated by the study team
2026-03-30

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.